ASCO poster presentation Unveils Preliminary results of Phase I Clinical Trial involving Intravenous Administration of GL-ONC1 to Patients with Advanced Solid Tumor Cancers
Preliminary results of the Phase 1 study being conducted at Royal Marsden Hospital (Surrey, UK) involving intravenous administration of GL-ONC1 in patients with advanced solid tumor cancers were presented during poster sessions by the study’s principal investigators* at three international meetings in late 2010 and at the American Society of Clinical Oncology (ASCO) meeting in Chicago in June 2011. While the clinical trial is ongoing and in its final stages, the following summary of preliminary results [http://genelux.com/files/ASCO-poster-Final.jpg] was presented at ASCO.
Conclusion: Systemically-administered GL-ONC1 is well tolerated with minimal toxicity and preliminary evidence of anti-tumour activity.
Poster entitiled: A Phase I clinical trial of a genetically modified and imageable oncolytic vaccinia virus GL-ONC1 with clinical green fluorescent protein (GFP) imaging; Presented by: Joanna Vitfell-Pedersen, Elena Karapanagiotou, Andrea Biondo, Martina Puglisi, Katie Denholm, Nina Tunarin, Salem Sassi, Johann De-Bono and Kevin Harrington (Royal Marsden Hospital NHS Foundation Trust/Institute of Cancer Research, Sutton, Surrey, United Kingdom)